Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accumulated Expenses: 2017-2025

Historic Accumulated Expenses for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $16.0 million.

  • Dianthus Therapeutics' Accumulated Expenses rose 106.79% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 106.79%. This contributed to the annual value of $13.1 million for FY2024, which is 101.01% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Accumulated Expenses of $16.0 million as of Q3 2025, which was up 14.14% from $14.0 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Accumulated Expenses ranged from a high of $16.0 million in Q3 2025 and a low of $3.2 million during Q2 2023.
  • For the 3-year period, Dianthus Therapeutics' Accumulated Expenses averaged around $8.8 million, with its median value being $7.7 million (2024).
  • Per our database at Business Quant, Dianthus Therapeutics' Accumulated Expenses tumbled by 44.33% in 2023 and then spiked by 139.01% in 2025.
  • Over the past 4 years, Dianthus Therapeutics' Accumulated Expenses (Quarterly) stood at $6.6 million in 2022, then dropped by 1.57% to $6.5 million in 2023, then surged by 101.01% to $13.1 million in 2024, then spiked by 106.79% to $16.0 million in 2025.
  • Its last three reported values are $16.0 million in Q3 2025, $14.0 million for Q2 2025, and $8.0 million during Q1 2025.